Key result
Oral sildenafil for 3 months significantly reduced mean pulmonary artery pressure from 55.8 to 50.4 mmHg (p=0.038) and pulmonary vascular resistance (p=0.009) in pulmonary hypertension.
Why the study?
Does sildenafil improve pulmonary haemodynamics and clinical status in patients with pulmonary hypertension?
Population
10 patients with pulmonary hypertension (8 females, mean age 34.5+/-3.3 years)
Design
Case_series
Follow-up
3 months
Authors
Loading...
Hypothesis-generating for sildenafil in pulmonary hypertension; leaves open efficacy and safety pending randomized trials.
Does sildenafil improve pulmonary haemodynamics and clinical status in patients with pulmonary hypertension?
Absolute Event Rate: 50.4% vs 55.8%
p-value: p=0.038
Sildenafil improves pulmonary hemodynamics and exercise capacity in patients with pulmonary hypertension over a 3-month period.
Ghada Mikhail (2004) studied pulmonary hypertension (n=10). Sildenafil was evaluated on mean pulmonary artery pressure (p=0.038). Oral sildenafil for 3 months significantly reduced mean pulmonary artery pressure from 55.8 to 50.4 mmHg (p=0.038) and pulmonary vascular resistance (p=0.009) in pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: